- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE cutoff hurts Star's annual results
The termination of a CT component supply contract between StarTechnologies and GE Medical Systems has resulted in a major dropin revenues for Star. The Sterling, VA, company reported financialresults for fiscal 1996 (end-March) that indicated revenues
The termination of a CT component supply contract between StarTechnologies and GE Medical Systems has resulted in a major dropin revenues for Star. The Sterling, VA, company reported financialresults for fiscal 1996 (end-March) that indicated revenues of$4.3 million, compared with $21.6 million the year before, whenthe agreement was still in effect. Star posted a loss of $4 millionfor the year, compared with net income of $1.2 million in 1995.
Star had been supplying GE with CT image reconstruction processorsuntil early 1995, when GE terminated the relationship. A disputebetween the companies went to an arbitration panel, which awardedStar $9.1 million (SCAN 3/27/96). GE is trying to have the rulingoverturned.
Star CEO Robert Compton said that 1996 was a transitional yearfor the company. The firm downsized in June 1995 and has beenworking with an investment banking firm to examine strategic opportunities,including acquisitions. It is also working to bring a new lineof image management products to market.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
